DexCom, Inc. (NASDAQ:DXCM) – Analysts at William Blair cut their Q4 2017 earnings estimates for shares of DexCom in a research report issued on Thursday. William Blair analyst M. Kaczor now expects that the medical device company will post earnings of $0.02 per share for the quarter, down from their prior forecast of $0.09. William Blair also issued estimates for DexCom’s Q1 2018 earnings at ($0.23) EPS, Q2 2018 earnings at ($0.13) EPS, Q3 2018 earnings at ($0.12) EPS, Q4 2018 earnings at ($0.10) EPS and FY2018 earnings at ($0.57) EPS.

DXCM has been the topic of several other research reports. ValuEngine upgraded shares of DexCom from a “sell” rating to a “hold” rating in a report on Monday. Piper Jaffray Companies reiterated a “buy” rating and issued a $78.00 price target on shares of DexCom in a report on Wednesday, July 12th. Wedbush reiterated an “outperform” rating and issued a $76.00 price target (down previously from $85.00) on shares of DexCom in a report on Thursday, September 28th. Oppenheimer Holdings, Inc. set a $92.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Wednesday, August 2nd. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $62.00 price target (down previously from $90.00) on shares of DexCom in a report on Thursday, September 28th. One analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $70.69.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/q4-2017-eps-estimates-for-dexcom-inc-dxcm-cut-by-analyst/1685312.html.

Shares of DexCom (NASDAQ:DXCM) traded up $0.18 during trading on Monday, hitting $50.12. 414,030 shares of the stock traded hands, compared to its average volume of 3,190,000. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84. DexCom has a 1 year low of $42.62 and a 1 year high of $88.80.

A number of hedge funds and other institutional investors have recently bought and sold shares of DXCM. UBS Group AG lifted its holdings in DexCom by 11.1% in the 1st quarter. UBS Group AG now owns 20,317 shares of the medical device company’s stock worth $1,721,000 after purchasing an additional 2,038 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of DexCom by 3.1% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 227,240 shares of the medical device company’s stock worth $19,255,000 after acquiring an additional 6,813 shares in the last quarter. State Street Corp raised its holdings in shares of DexCom by 1.9% during the 1st quarter. State Street Corp now owns 1,512,262 shares of the medical device company’s stock worth $128,127,000 after acquiring an additional 28,311 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of DexCom by 12.3% during the 1st quarter. AQR Capital Management LLC now owns 74,211 shares of the medical device company’s stock worth $6,288,000 after acquiring an additional 8,137 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ raised its holdings in shares of DexCom by 175.7% during the 1st quarter. Skandinaviska Enskilda Banken AB publ now owns 11,029 shares of the medical device company’s stock worth $934,000 after acquiring an additional 7,029 shares in the last quarter.

In other DexCom news, EVP Richard Doubleday sold 1,635 shares of the business’s stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $44.82, for a total transaction of $73,280.70. Following the completion of the sale, the executive vice president now directly owns 65,049 shares in the company, valued at approximately $2,915,496.18. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Andrew K. Balo sold 3,244 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $71.18, for a total value of $230,907.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,208 shares of company stock valued at $1,597,567. 1.70% of the stock is owned by insiders.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.